

JÃ©rome Bertherat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8402650/publications.pdf>

Version: 2024-02-01

135
papers

11,694
citations

26567

56
h-index

28224

105
g-index

136
all docs

136
docs citations

136
times ranked

7548
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated genomic characterization of adrenocortical carcinoma. <i>Nature Genetics</i> , 2014, 46, 607-612.	9.4	560
2	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	7.7	482
3	Mutations of β -Catenin in Adrenocortical Tumors: Activation of the Wnt Signaling Pathway Is a Frequent Event in both Benign and Malignant Adrenocortical Tumors. <i>Cancer Research</i> , 2005, 65, 7622-7627.	0.4	415
4	Mutations in Regulatory Subunit Type 1A of Cyclic Adenosine 5'-Monophosphate-Dependent Protein Kinase (PRKAR1A): Phenotype Analysis in 353 Patients and 80 Different Genotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2085-2091.	1.8	399
5	Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3775-3784.	1.8	369
6	Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2650-2655.	1.8	361
7	Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome. <i>New England Journal of Medicine</i> , 2014, 370, 1019-1028.	13.9	355
8	Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival. <i>Journal of Clinical Oncology</i> , 2009, 27, 1108-1115.	0.8	341
9	ARMC5 Mutations in Macronodular Adrenal Hyperplasia with Cushing's Syndrome. <i>New England Journal of Medicine</i> , 2013, 369, 2105-2114.	13.9	319
10	A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. <i>Nature Genetics</i> , 2006, 38, 794-800.	9.4	316
11	Gene Expression Profiling of Human Adrenocortical Tumors Using Complementary Deoxyribonucleic Acid Microarrays Identifies Several Candidate Genes as Markers of Malignancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1819-1829.	1.8	233
12	Adrenocortical cancer: pathophysiology and clinical management. <i>Endocrine-Related Cancer</i> , 2007, 14, 13-28.	1.6	220
13	Constitutive β -catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. <i>Human Molecular Genetics</i> , 2010, 19, 1561-1576.	1.4	209
14	Prognostic Parameters of Metastatic Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 148-154.	1.8	205
15	High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E161-E171.	1.8	196
16	Pangenomic Classification of Pituitary Neuroendocrine Tumors. <i>Cancer Cell</i> , 2020, 37, 123-134.e5.	7.7	186
17	Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. <i>Cancer Research</i> , 2003, 63, 5308-19.	0.4	185
18	Intraadrenal Corticotropin in Bilateral Macronodular Adrenal Hyperplasia. <i>New England Journal of Medicine</i> , 2013, 369, 2115-2125.	13.9	176

#	ARTICLE	IF	CITATIONS
19	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , 2015, 28, 807-821.	2.9	176
20	Molecular Analysis of the Cyclic AMP-Dependent Protein Kinase A (PKA) Regulatory Subunit 1A (PRKAR1A) Gene in Patients with Carney Complex and Primary Pigmented Nodular Adrenocortical Disease (PPNAD) Reveals Novel Mutations and Clues For Pathophysiology: Augmented PKA Signaling is Associated with Adrenal Tumorigenesis in PPNAD. <i>American Journal of Human Genetics</i> , 2002, 71, 1433-1442.	2.6	173
21	Mutations of the PRKAR1A Gene in Cushing's Syndrome due to Sporadic Primary Pigmented Nodular Adrenocortical Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4324-4329.	1.8	165
22	The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E997-E1004.	1.8	163
23	Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. <i>Endocrine-Related Cancer</i> , 2014, 21, 567-577.	1.6	161
24	Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. <i>European Journal of Endocrinology</i> , 2005, 153, 477-487.	1.9	158
25	Cushing's disease. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 607-623.	2.2	157
26	WNT/ β -catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. <i>Human Molecular Genetics</i> , 2014, 23, 889-905.	1.4	157
27	Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. <i>Human Mutation</i> , 2010, 31, 369-379.	1.1	156
28	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. <i>Nature Communications</i> , 2015, 6, 6044.	5.8	153
29	Transcriptome Analysis Reveals that p53 and β -Catenin Alterations Occur in a Group of Aggressive Adrenocortical Cancers. <i>Cancer Research</i> , 2010, 70, 8276-8281.	0.4	134
30	ARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional Consequences. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E926-E935.	1.8	132
31	Mutational signature analysis identifies MUTH1 deficiency in colorectal cancers and adrenocortical carcinomas. <i>Journal of Pathology</i> , 2017, 242, 10-15.	2.1	130
32	β -Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 328-336.	3.2	128
33	Wnt/ β -Catenin and β -Cyclic Adenosine 5'-Monophosphate/Protein Kinase A Signaling Pathways Alterations and Somatic β -Catenin Gene Mutations in the Progression of Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4135-4140.	1.8	127
34	Macronodular Adrenal Hyperplasia due to Mutations in an Armadillo Repeat Containing 5 (ARMC5) Gene: A Clinical and Genetic Investigation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1113-E1119.	1.8	127
35	PRKAR1A Mutation Associated with Primary Pigmented Nodular Adrenocortical Disease in 12 Kindreds. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1943-1949.	1.8	116
36	Phosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 4016-4024.	3.2	114

#	ARTICLE	IF	CITATIONS
37	Wnt/ β -catenin signalling in adrenal physiology and tumour development. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 87-95.	1.6	111
38	Identification of a CpG Island Methylator Phenotype in Adrenocortical Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E174-E184.	1.8	110
39	Frequent Phosphodiesterase 11A Gene (<i>PDE11A</i>) Defects in Patients with Carney Complex (CNC) Caused by <i>PRKAR1A</i> Mutations: <i>PDE11A</i> May Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E208-E214.	1.8	108
40	Wnt/ β -Catenin Pathway Activation in Adrenocortical Adenomas Is Frequently due to Somatic CTNNB1-Activating Mutations, Which Are Associated with Larger and Nonsecreting Tumors: A Study in Cortisol-Secreting and -Nonsecreting Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E419-E426.	1.8	105
41	Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity. <i>Clinical Cancer Research</i> , 2007, 13, 844-850.	3.2	104
42	A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. <i>European Journal of Human Genetics</i> , 2008, 16, 1245-1253.	1.4	103
43	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	1.8	103
44	In Vivo and in Vitro Screening for Illegitimate Receptors in Adrenocorticotropin-Independent Macronodular Adrenal Hyperplasia Causing Cushing's Syndrome: Identification of Two Cases of Gonadotropin/Gastric Inhibitory Polypeptide-Dependent Hypercortisolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1302-1310.	1.8	99
45	Inactivation of the <i>APC</i> Gene Is Constant in Adrenocortical Tumors from Patients with Familial Adenomatous Polyposis but Not Frequent in Sporadic Adrenocortical Cancers. <i>Clinical Cancer Research</i> , 2010, 16, 5133-5141.	3.2	97
46	Cushing's Syndrome and Fetal Features Resurgence in Adrenal Cortex-Specific <i>Prkar1a</i> Knockout Mice. <i>PLoS Genetics</i> , 2010, 6, e1000980.	1.5	95
47	Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2010, 163, 129-138.	1.9	89
48	Primary Aldosteronism and <i>ARMC5</i> Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E900-E909.	1.8	89
49	Overexpression of Serotonin ₄ Receptors in Cisapride-Responsive Adrenocorticotropin-Independent Bilateral Macronodular Adrenal Hyperplasia Causing Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 248-254.	1.8	75
50	The Paradoxical Increase in Cortisol Secretion Induced by Dexamethasone in Primary Pigmented Nodular Adrenocortical Disease Involves a Glucocorticoid Receptor-Mediated Effect of Dexamethasone on Protein Kinase A Catalytic Subunits. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2406-2413.	1.8	75
51	Phosphodiesterase 11A (<i>PDE11A</i>) Gene Defects in Patients with ACTH-Independent Macronodular Adrenal Hyperplasia (AIMAH): Functional Variants May Contribute to Genetic Susceptibility of Bilateral Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2063-E2069.	1.8	75
52	Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma. <i>Journal of the Endocrine Society</i> , 2017, 1, 646-649.	0.1	75
53	Identification of novel genetic variants in phosphodiesterase 8B (<i>PDE8B</i>), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. <i>Clinical Endocrinology</i> , 2012, 77, 195-199.	1.2	72
54	Molecular Screening for a Personalized Treatment Approach in Advanced Adrenocortical Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4080-4088.	1.8	72

#	ARTICLE	IF	CITATIONS
55	The Ectopic Expression of the Gastric Inhibitory Polypeptide Receptor Is Frequent in Adrenocorticotropin-Independent Bilateral Macronodular Adrenal Hyperplasia, but Rare in Unilateral Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1980-1985.	1.8	67
56	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3526-3538.	1.8	65
57	Genetics of tumors of the adrenal cortex. <i>Endocrine-Related Cancer</i> , 2018, 25, R131-R152.	1.6	58
58	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1440.	3.4	57
59	MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors. <i>European Journal of Endocrinology</i> , 2018, 178, R215-R230.	1.9	56
60	Carney Complex. <i>Frontiers of Hormone Research</i> , 2013, 41, 50-62.	1.0	55
61	PRKAR1A mutations in primary pigmented nodular adrenocortical disease. <i>Pituitary</i> , 2006, 9, 211-219.	1.6	54
62	The ARMC5 gene shows extensive genetic variance in primary macronodular adrenocortical hyperplasia. <i>European Journal of Endocrinology</i> , 2015, 173, 435-440.	1.9	51
63	Adrenal incidentalomas. <i>Current Opinion in Oncology</i> , 2002, 14, 58-63.	1.1	49
64	Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2985-2993.	1.8	49
65	Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e307-e318.	1.8	45
66	Activating PRKACB somatic mutation in cortisol-producing adenomas. <i>JCI Insight</i> , 2018, 3, .	2.3	44
67	Genetics of primary bilateral macronodular adrenal hyperplasia: a model for early diagnosis of Cushing's syndrome?. <i>European Journal of Endocrinology</i> , 2015, 173, M121-M131.	1.9	43
68	Clinical and Pathophysiological Implications of Chromosomal Alterations in Adrenocortical Tumors: An Integrated Genomic Approach. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E301-E311.	1.8	41
69	The 'omics' of adrenocortical tumours for personalized medicine. <i>Nature Reviews Endocrinology</i> , 2014, 10, 215-228.	4.3	41
70	IGF2 Promotes Growth of Adrenocortical Carcinoma Cells, but Its Overexpression Does Not Modify Phenotypic and Molecular Features of Adrenocortical Carcinoma. <i>PLoS ONE</i> , 2014, 9, e103744.	1.1	40
71	Mechanisms of Disease: adrenocortical tumorsâ€™ molecular advances and clinical perspectives. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 632-641.	2.9	38
72	The role of ARMC5 in human cell cultures from nodules of primary macronodular adrenocortical hyperplasia (PMAH). <i>Molecular and Cellular Endocrinology</i> , 2018, 460, 36-46.	1.6	38

#	ARTICLE	IF	CITATIONS
73	Adrenal GPR expression and chromosome 19q13 microduplications in GIP-dependent Cushingâ€™s syndrome. <i>JCI Insight</i> , 2017, 2, .	2.3	38
74	Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. <i>European Journal of Endocrinology</i> , 2014, 170, 385-391.	1.9	37
75	EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. <i>Human Molecular Genetics</i> , 2016, 25, ddw136.	1.4	37
76	Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelsonâ€™s tumor. <i>European Journal of Endocrinology</i> , 2018, 178, 57-63.	1.9	37
77	mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD). <i>Human Molecular Genetics</i> , 2014, 23, 5418-5428.	1.4	36
78	Dosage-dependent regulation of <i>VAV2</i> expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. <i>Science Signaling</i> , 2017, 10, .	1.6	35
79	Identification of Gene Expression Profiles Associated With Cortisol Secretion in Adrenocortical Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1109-E1121.	1.8	33
80	Role of ACTH in the Interactive/Paracrine Regulation of Adrenal Steroid Secretion in Physiological and Pathophysiological Conditions. <i>Frontiers in Endocrinology</i> , 2016, 7, 98.	1.5	33
81	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3491-3498.	1.8	33
82	Analysis of ARMC5 expression in human tissues. <i>Molecular and Cellular Endocrinology</i> , 2017, 441, 140-145.	1.6	33
83	What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics. <i>Endocrine Pathology</i> , 2021, 32, 102-133.	5.2	33
84	Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation. <i>Modern Pathology</i> , 2018, 31, 1708-1716.	2.9	29
85	Adrenocortical Cancer in Carney Complex: A Paradigm of Endocrine Tumor Progression or an Association of Genetic Predisposing Factors?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 387-390.	1.8	27
86	The Genetics of Adrenocortical Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 311-334.	1.2	27
87	KDM1A inactivation causes hereditary food-dependent Cushing syndrome. <i>Genetics in Medicine</i> , 2022, 24, 374-383.	1.1	27
88	¹⁸ F-fluorocholine PET/CT in MEN1 Patients with Primary Hyperparathyroidism. <i>World Journal of Surgery</i> , 2020, 44, 3761-3769.	0.8	25
89	Update on primary bilateral macronodular adrenal hyperplasia (PBMAH). <i>Endocrine</i> , 2021, 71, 595-603.	1.1	25
90	Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma. <i>Endocrine-Related Cancer</i> , 2018, 25, L13-L17.	1.6	22

#	ARTICLE	IF	CITATIONS
91	The 10 Hounsfield units unenhanced computed tomography attenuation threshold does not apply to cortisol secreting adrenocortical adenomas. <i>European Journal of Endocrinology</i> , 2015, 173, 325-332.	1.9	21
92	Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3345-3352.	1.8	21
93	Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4604-4611.	1.8	19
94	Surgical management of pancreatic neuroendocrine tumors: an introduction. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 1089-1100.	1.1	19
95	Molecular Basis of Primary Aldosteronism and Adrenal Cushing Syndrome. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa075.	0.1	19
96	Long-term follow-up and predictors of recurrence of Cushing's disease. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	19
97	Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene <i>ARMC5</i> in 352 unselected patients. <i>European Journal of Endocrinology</i> , 2022, 187, 123-134.	1.9	18
98	Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. <i>Scientific Reports</i> , 2017, 7, 49.	1.6	17
99	Genomic classification of benign adrenocortical lesions. <i>Endocrine-Related Cancer</i> , 2021, 28, 79-95.	1.6	17
100	The Great Imitator in Endocrinology: A Painful Hypophysitis Mimicking a Pituitary Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2837-2840.	1.8	16
101	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. <i>European Journal of Endocrinology</i> , 2019, 180, 311-320.	1.9	16
102	Update of Genetic and Molecular Causes of Adrenocortical Hyperplasias Causing Cushing Syndrome. <i>Hormone and Metabolic Research</i> , 2020, 52, 598-606.	0.7	15
103	Cullin 3 targets the tumor suppressor gene <i>ARMC5</i> for ubiquitination and degradation. <i>Endocrine-Related Cancer</i> , 2020, 27, 221-230.	1.6	15
104	Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2019, 10, 487.	1.5	14
105	The EuRRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8743.	1.2	13
106	Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia. <i>Endocrine-Related Cancer</i> , 2020, 27, 403-413.	1.6	13
107	Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101294.	2.2	12
108	Cell-To-Cell Communication in Bilateral Macronodular Adrenal Hyperplasia Causing Hypercortisolism. <i>Frontiers in Endocrinology</i> , 2015, 6, 34.	1.5	11

#	ARTICLE	IF	CITATIONS
109	Surgical management of insulinoma over three decades. <i>Hpb</i> , 2021, 23, 1799-1806.	0.1	11
110	Diseases Predisposing to Adrenocortical Malignancy (Liã€“Fraumeni Syndrome, Beckwithã€“Wiedemann) Tj ETQq0,0,0 rgBT /Overlock 1	0.5	11
111	Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma. <i>Endocrine Connections</i> , 2020, 9, 705-714.	0.8	10
112	Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients. <i>European Journal of Endocrinology</i> , 2022, 187, 315-322.	1.9	10
113	The role of adrenal venous sampling (AVS) in primary bilateral macronodular adrenocortical hyperplasia (PBMAH): a study of 16 patients. <i>Endocrine</i> , 2022, 76, 434-445.	1.1	9
114	Hepato-pancreato-biliary lesions are present in both Carney complex and McCune Albright syndrome. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 344-345.	1.6	8
115	Choroidal imaging in patients with Cushing syndrome. <i>Acta Ophthalmologica</i> , 2021, 99, 533-537.	0.6	8
116	Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 776-787.	1.2	7
117	Adrenalectomy during pregnancy: A 15-year experience at a tertiary referral center. <i>Surgery</i> , 2020, 168, 335-339.	1.0	7
118	ARMC5 variants in PRKAR1A-mutated patients modify cortisol levels and Cushingã€™s syndrome. <i>Endocrine-Related Cancer</i> , 2020, 27, 509-517.	1.6	7
119	PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A. <i>Endocrine-Related Cancer</i> , 2020, 27, 647-656.	1.6	7
120	ARMC5 mutation in a Portuguese family with primary bilateral macronodular adrenal hyperplasia (PBMAH). <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2017, 2017, .	0.2	6
121	First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1-1.	0.8	6
122	Adrenalectomy for incidentaloma: lessons learned from a singleã€“centre series of 274 patients. <i>ANZ Journal of Surgery</i> , 2018, 88, 468-473.	0.3	5
123	Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. <i>Endocrine Connections</i> , 2018, 7, 1409-1414.	0.8	5
124	Link between steroidogenesis, the cell cycle, and PKA in adrenocortical tumor cells. <i>Molecular and Cellular Endocrinology</i> , 2020, 500, 110636.	1.6	3
125	PDE 2015: cAMP Signaling, Protein Kinase A (PKA) and Phosphodiesterases (PDEs): How Genetics Changed the Way We Look at One of the Most Studied Signaling Pathways. <i>Hormone and Metabolic Research</i> , 2017, 49, 237-239.	0.7	2
126	Perioperative outcomes of pheochromocytoma/paraganglioma surgery preceded by Takotsubo-like cardiomyopathy. <i>Surgery</i> , 2022, 172, 913-918.	1.0	2

#	ARTICLE	IF	CITATIONS
127	Letter to the Editor from Berthon: "Cardiac Myxoma Caused by Fumarate Hydratase Gene Deletion in Patient With Cortisol-Secreting Adrenocortical Adenoma". Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4183-e4184.	1.8	1
128	ENDO-ERN ON RARE ENDOCRINE CONDITIONS: Endo-ERN in its fifth year: a pinch of care, science, curiosity and new horizons. Endocrine Connections, 2022, 11, .	0.8	1
129	Genetics of adrenal tumors. Presse Medicale, 2018, 47, e107-e108.	0.8	0
130	Prognostic factors of overall survival of stage III or IV adrenocortical carcinomas (ACC): A multicenter ENS@T study.. Journal of Clinical Oncology, 2014, 32, 4106-4106.	0.8	0
131	OR02-6 Mass Spectrometry-Based Steroid Profiling Inprimary Bilateral Macronodular Adrenocortical Hyperplasia. Journal of the Endocrine Society, 2019, 3, .	0.1	0
132	SUN-444 Efficacy and Safety of Dopamine Agonists in Psychiatric Patients Treated with Antipsychotics and Presenting a Macroprolactinoma. Journal of the Endocrine Society, 2019, 3, .	0.1	0
133	CRH-Receptor Molecular Imaging Reveals the Intimacy of Corticotroph Adenomas. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1902-1904.	1.8	0
134	SUN-714 Phenotype of Patients Carrying the c.709(-7-2)del PRKAR1A Mutation in a Large Cohort of 41 Patients. Journal of the Endocrine Society, 2020, 4, .	0.1	0
135	Decreased steroidogenic enzyme activity in benign adrenocortical tumors is more pronounced in bilateral lesions as determined by steroid profiling in LCMSMS during ACTH stimulation test. Endocrine Connections, 2022, , .	0.8	0